Charting A Regulatory Course For Your Combination Product, Part 1

Did you know that approximately 30% of all new healthcare products currently under development are combination products? But, as is the case with so many burgeoning medical technology segments, the regulatory pathway for combination products is constantly changing and often misunderstood. In this two-part podcast, Michael Drues, president of Vascular Sciences and author of the Guerilla Regulatory Strategy series, provides practical regulatory strategy advice to combo product developers by walking through several real-world examples. Listen to Part 2.

Related podcasts:

• How To Capitalize On The Companion Diagnostics Boom
• Bringing 3D-Printed Medical Devices To Market In An Uncertain Regulatory Environment

Michael Drues can be contacted via email or LinkedIn.